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The Development of a e-Polycaprolactone Scaffold
for Central Nervous System Repair
Peter S. Donoghue, BSc, PhD,1 Rebecca Lamond, BSc,1 Stephanie D. Boomkamp, BSc, PhD,1
Tao Sun, BSc, PhD,2,3 Nikolaj Gadegaard, BSc, MSc, PhD,4
Mathis O. Riehle, BSc, PhD,2 and Susan C. Barnett, BSc, PhD1
Potential treatment strategies for the repair of spinal cord injury (SCI) currently favor a combinatorial approach
incorporating several factors, including exogenous cell transplantation and biocompatible scaffolds. The use of
scaffolds for bridging the gap at the injury site is very appealing although there has been little investigation into
the central nervous system neural cell interaction and survival on such scaffolds before implantation. Previously,
we demonstrated that aligned microgrooves 12.5–25 mm wide on e-polycaprolactone (PCL) promoted aligned
neurite orientation and supported myelination. In this study, we identify the appropriate substrate and its
topographical features required for the design of a three-dimensional scaffold intended for transplantation in
SCI. Using an established myelinating culture system of dissociated spinal cord cells, recapitulating many of the
features of the intact spinal cord, we demonstrate that astrocytes plated on the topography secrete soluble
factors(s) that delay oligodendrocyte differentiation, but do not prevent myelination. However, as myelination
does occur after a further 10–12 days in culture, this does not prevent the use of PCL as a scaffold material as part
of a combined strategy for the repair of SCI.
Introduction
The intrinsic inability of central nervous system (CNS)neurons to regenerate, coupled with the formation of a
gliotic scar are the major contributing factors to the irrepa-
rable nature of spinal cord injury (SCI).1,2 As a consequence,
numerous treatment strategies have been considered in-
cluding, exogenous cell transplantation and disruption of
the glial scar by biological and pharmacological agents, with
limited success. Moreover, after cell transplantation, even
with extensive in-growth, axonal orientation is often random
within the lesion, with few axons exiting the graft and en-
tering the distal host tissue.1,3,4 To overcome these specific
problems, implantation of biocompatible oriented scaffolds
of biodegradable polymers has been designed to promote
aligned axonal outgrowth across the lesion.5–9
Numerous potential substrates have been investigated for
use in scaffold design, including (1) biocompatible hard de-
gradable polymers, for example, e-polycaprolactone (PCL),10
poly-L-lactide (PLLA),11 poly(lactic-co-glycolic acid) (PLGA),
and chitosan, or (2) hydrogels both naturally occurring, for
example, agarose12 and collagen, or synthetic, each posses-
sing unique properties and characteristics. Polymers can also
be blended with each other, to combine properties of their
constituent materials including PCL/PGLA13 and PCL/
chitosan.14,15 They can be combined with other treatment
strategies, such as cell transplants including glia that is,
Schwann cells or olfactory ensheathing cells (OECs), neural
progenitor cells, or stem cells16–19; or impregnated with
compounds noted for their neurotrophic properties or ability
to disrupt the inhibitory scar environment. This combinato-
rial approach has demonstrated some success in the en-
couragement of neurite outgrowth or functional recovery,
such as the combination of a PCL scaffold with neural pro-
genitor cell implantation and perfusion with chondroitinase
ABC,18 or PCL nanofibers impregnated with the brain-
derived neurotrophic factor.20
Previously, our group has reported that the inclusion of
microgrooves on a PCL substrate promotes the aligned
growth of axons within a CNS culture21 and can be in-
corportated into a three-dimensional (3D) Swiss roll style
scaffold by rolling up a porous, patterned PCL sheet.22 The
pores enable mass transfer within the 3D scaffold and pre-
vious work has demonstrated that a pore diameter of at least
200mm prevents occlusion by astrocytes.22,23 This 3D scaffold
will eventually be coated with glial cells, as part of a
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combinatorial approach to treat SCI, to promote the in-
growth of endogenous CNS cells in an aligned manner to aid
crossing the graft. Before the implantation of this compli-
cated 3D Swiss roll, we have adopted a systematic approach
to investigate the different features of the scaffold design to
fully assess their potential effects on CNS cells using disso-
ciated rat spinal cord cells. These cells interact to mimic the
complex cellular interactions of CNS cells in vivo.24–26 Al-
though many studies have primarily investigated biocom-
patibility, cytotoxicity, and the immune response following
implantation,27 we have focused on how the host CNS cells,
including astrocytes, neurons, microglia, and their myeli-
nating glia respond to the scaffold design with emphasis on
differentiation as a read out, which indicates the potential
effectiveness of the scaffold to support repair in the CNS.
Materials and Methods
Cell seeding
Preparation of the striatal neurosphere-derived astro-
cytes. Myelinating CNS cultures were set up as previously
outlined,24,25 with a couple of minor modifications. They
comprise a monolayer of astrocytes on top of which are
plated mixed rat spinal cord cells. Astrocytes are essential for
cell survival and myelination.24 Briefly, striatum were col-
lected from P1 Sprague-Dawley rats in Liebowitz (L15;
Invitrogen) media and dissociated mechanically before sus-
pension in neurosphere media (Dulbecco’s modified Eagle’s
medium, DMEM/F12 (1:1), 0.6% glucose, 2 mM glutamine
(Invitrogen), insulin (25 mg/mL; Sigma), 5 mM Hepes
(Sigma), 0.105% NaHCO3 (Sigma), 5000 IU/mL penicillin
(Invitrogen), 5 mg/mL streptomycin (Invitrogen), 100 mg/mL
apotransferrin, 20 nM progesterone, 60 mM putrescine, and
30 nM sodium selenite (all Sigma) supplemented with
20 ng/mL mouse submaxillary gland epidermal growth
factor (EGF; R&D systems) and cultured as neurospheres for
7–10 days at 37C, 7% CO2, with supplementation of the
media every alternate day.
Neurospheres were differentiated into astrocytes in a
T150-cm2 flask using the low-glucose DMEM (Invitrogen)
containing 10% fetal bovine serum (referred to as 10% FBS)
for 7–8 days. Since astrocytes derived from neurospheres or
the cortex support myelination in these cultures, we used
neurosphere-derived astrocytes as they more rapidly gener-
ate many purified cells.24,25 Differentiating astrocytes in a
flask before seeding enabled the calculation of defined cell
numbers sufficient to form a confluent monolayer after
seeding onto a glass coverslip or polymer substrate. This
compensated for any difficulties assessing if the monolayer
was confluent due to the opacity of the polymers. Astrocytes
were passaged with trypsin/EDTA (0.25%, Invitrogen) and
plated onto either poly-l-lysine (PLL, Sigma, 13mg/mL)-
treated glass coverslips (VWR International) or a polymer
substrate at a density of 200,000 cells per 100 mL. The astro-
cytes were maintained in 10% FBS.
Preparation of the myelinating cultures. The spinal cord
from E15 Sprague-Dawley rat embryos were dissected, the
meninges removed, chopped, and digested in trypsin and
collagenase for 15 min followed by enzymatic inhibition with
a soybean trypsin inhibitor (0.52 mg/mL), bovine serum al-
bumin (3.0 mg/mL), and DNase (0.04 mg/mL; all Sigma).
The cell suspension was centrifuged at 12,000 rpm for 5 min,
resuspended in plating media (DMEM 21885, containing
20% horse serum, HBSS, L-glutamine), plated onto astrocyte
monolayers at 150,000 cells per 100 mL and left for 2 h at 37C,
7% CO2 before feeding with a mix of plating media and
differentiation media (DMEM 196966, Invitrogen, 50 nM
hydrocortisone, 10 ng/mL biotin, 4 mM progesterone, 20 mM
putrescine, 6 mM selenium, 1 m/mL apotransferrin, supple-
mented with 10 mg/mL insulin (all Sigma). The cultures were
maintained with fresh differentiation media on alternate
feeding days, with the insulin supplement removed from
12 days in vitro (DIV).
Construct preparation
Preparation of polymer-coated coverslips for materials
testing. Several polymers were used in testing compatibil-
ity with survival and differentiation of the myelinating cul-
tures, including PCL (high molecular weight: 90,000 and low
molecular weight: 45,000, both Sigma); Polycarbonate (PCB,
Bayer Makrolon OD2015); Polystyrene (PS, Proprietary
grade); PLLA (Ingeo Biopolymer D3001, Nature Works
LLC); Poly(methyl) methacrylate (PMMA; Evonik Degussa
Plexiglas 6N). All were dissolved in chloroform at 10%
(w/v), and used for spin-coating coverslips. Glass coverslips
(13 mm diameter) were placed in a spin coater and 150mL of
polymer solution applied before spinning at 2000 rpm for
15 s, with 200 rpm/s acceleration and 200 rpm/s decelera-
tion. Polydimethylsiloxane (PDMS; Dow Corning) was pre-
pared by mixing Sylgard 184 at a ratio 10:1 of base and
curing agent, degassed for 20 min, and cast against a fluori-
nated silicon wafer to achieve a flat substrate.
Preparation of the PCL membrane. The PCL membranes
were prepared by washing PCL pellets (MW: 45,000 or
90,000; Sigma) with methanol, with subsequent drying and
dissolution into chloroform, (15% w/v, concentration) over-
night on a shaker platform. The PCL/chloroform solution
was then applied to a silicon wafer either with a flat surface,
or, for a porous PCL membrane, with equidistant cylindrical
pillars across its surface. Once the PCL solution was applied
to the wafer, it was spin coated at 1000 rpm for 30 s, ramp
200 rpm/s, and the chloroform allowed to evaporate in
sterile air. The resultant PCL membrane, which was *20 mm
thick, was then wetted with 70% ethanol before removing
from the wafer to avoid disruption of membrane integrity.
The microgrooved topography was applied using the hot
embossing protocol previously described.20 Briefly, the PCL
membrane was sandwiched between an unpatterned PDMS
mask and a PDMS mask with an aligned micropattern. Once
cooled, the patterned PCL membrane could be used in fur-
ther construct preparation, with 0.5-cm · 1-cm sections being
cut and attached to a support scaffold, as required for their
appropriate maintenance in culture. The support scaffold
was constructed using 4 polycarbonate struts arranged in
two parallel rows, with one row resting on the other forming
a square and the struts were stuck together using molten
PCL. The PCL membrane could then be attached spanning
between parallel rows, leaving a 0.6-cm · 0.5-cm area for cell
seeding. The scaffolds were placed on a coverslip for cell
seeding as a meniscus in 100mL (as with the glass coverslips),
and transferred to a larger polycarbonate scaffold to keep the
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membrane suspended. The fabrication scheme is summa-
rized in Figure 1. Unpatterned membranes were used to
assess if the micropattern and/or PCL affected differentia-
tion within the myelinating cultures.
Preparation of the polymers for cell culture. In all ex-
periments, the hydrophobicity of the polymers was reduced
with air plasma using a Harrick Plasma Cleaner (Harrick
Plasma) at Hi settings (740 V DC, 40 mA DC, 29.6 W) for
5 min before the application of PLL and use in cell culture.
Immunocytochemistry
For intracellular markers, cells were fixed in 4% parafor-
maldehyde and permeabilized with phosphate-buffered
saline containing 0.2% (w/v) gelatin and 0.1% (v/v) Triton
X-100TM. Cell surface markers (i.e., the O4 antibody, A2B5,
and the chondroitin sulfate proteoglycan NG2) were applied
to live cells, followed by Alexa Fluor anti-mouse IgM or anti-
rabbit secondary (Cambridge Biosciences), before methanol
fixation. The primary antibodies used were SMI-31 (1:1,500,
mouse monoclonal IgG1, Abcam, labels phosphorylated
neurofilament), AA3, raised against the proteolipid protein
(PLP-DM20, 1:100, anti-rat) and defines mature myelin,28 the
astrocytic marker, the glial fibrillary acidic protein (GFAP,
1:100, rabbit polyclonal; DAKO), O4 (1:1, hybridoma, IgM,
oligodendrocyte marker), and A2B5, (1:1, hybridoma, IgM,
oligodendrocyte precursor cell (OPC) marker) both gifts
from Mark Noble29 and NG2 (1:100, rabbit polyclonal, Che-
micon, early OPC). The secondary antibodies were from the
Alexa Fluor range (1:100; Invitrogen). Nuclei were visualized
using DAPI included in the hard set mountant (Fluoro-Gel;
Interchim).
Imaging
Images were captured using an Olympus BX51 micro-
scope with Q imaging software Images and analyzed using
Image Pro Plus (Media Cybernetics).
Quantification and statistics
Quantification of myelination. To quantify myelination as
defined by the percentage of fibers ensheathed by a myelin
sheath, the cultures were labeled with SMI-31 (green), anti-
PLP myelin (red), and DAPI (blue). Ten images per coverslip
were acquired at · 10 magnification as previously de-
scribed23 and initially opened using ImageJ with the blue
(DAPI) channel removed. The red and green images were
then opened with Adobe Photoshop Elements 7.0 and areas
of myelin that was a clear sheath were overlaid by hand
using a brush tool in blue in a new, lightened layer. The
percentage of myelination was calculated using ImageJ by
taking the neurite density, (as recorded by the red pixels),
and calculating the percentage of neurites ensheathed by
myelin (blue area in pixels). The calculations were produced
using our own macro in ImageJ. For comparison of values
between groups of conditions, data were analyzed by
calculating ratios and analyzing these with one-sample
Student’s t tests, using 1 as the null hypothesis mean. The
mean of a minimum of 3 experiments per condition in du-
plicate was used, and all values are expressed as means –
SEM. Significance was represented using p-values, where
values – 0.05 were considered significant for comparisons
using only two samples, and are indicated by an asterisk on
images. A Bonferroni correction was applied when there
were multiple samples being compared with the control,
with a lower p-value being used to determine significance.
Analysis of cell differentiation. Images of the myelinating
cultures labeled with oligodendrocyte lineage markers: anti-
NG2, the A2B5, and O4 antibody were opened using ImageJ
and the channels split, with each cell labeled being identified
and calculated as a percentage of the total number of DAPI-
stained nuclei. O4 expression differed in that the exten-
sive arborisation of the O4-positive cells made identifying
individual cells difficult, so the percentage coverage by O4-
positive processes was calculated and divided by the total
FIG. 1. Schematic for construct preparation. The porous e-polycaprolactone (PCL) membrane is prepared by spin-coating
(A) and subsequently hot-embossed with an aligned micropattern using a polydimethylsiloxane (PDMS) stamp (B). The
resultant porous, micropatterned PCL membrane is then fixed to a polycarbonate scaffold (C, D) and mounted on a 13-mm
glass coverslip (E) for seeding with the appropriate cell type (F), which sit in a meniscus as with a control coverslip. The
coverslip was subsequently removed after the cells had settled and the construct suspended on a larger polycarbonate
scaffold. Color images available online at www.liebertpub.com/tea
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cell number as indicated by DAPI staining. All experiments
were conducted in duplicate with at least 3–5 separate ex-
periments.
Results
The percentage of myelination was greater in cultures
plated on PCL compared to other substrates
To determine which material would be most suitable for
transplantation into the CNS and be supportive of endoge-
nous neural cell survival and differentiation, we studied their
ability to support myelination in mixed spinal cord cell cul-
tures. In general, the maximum percentage of myelination in
the cultures ranges from 2%–10% after 28 DIV as many of the
fibers generated in culture are interneurons. Previously, we
have demonstrated that myelin is compacted25 and formed
correctly with the correct location of nodal proteins in these
cultures.24 Comparisons were made to a positive control of
cultures grown on a PLL-coated glass coverslip (to assure us
that the cultures are differentiating correctly), and the fol-
lowing PLL-coated test substrates: PCL (low (L) and high (H)
Mw), PC, PMMA, PS, PLLA, and PDMS (Fig. 2). Previous
work has demonstrated the usefulness of this control in
comparing the ability of several reactive astrocyte pheno-
types in supporting myelination.30
The neurite density (SMI-31 immunoreactivity) on the
polymer substrates was comparable to that of control glass
coverslips, an important indicator of neuronal survival and
process extension, but myelination was significantly lower
(n= 3, t-test, Bonferroni corrected, *p < 0.05) on all polymer
substrates when compared to the control. The lower molec-
ular weight PCL supported the highest level of myelination
of all the polymers, but was not suitable for further use,
being too fragile to survive the hot embossing and subse-
quent 3D manipulations intact. Expansion of the culture time
beyond 28 days on these various substrates resulted in
nonviable cultures and could not be analyzed (suggesting
lack of compatability for long-term cultures) except for the
two PCL substrates. The high molecular weight PCL was
considered the optimal substrate.
FIG. 2. PCL is the most suitable polymer for supporting myelination in mixed neural cell cultures. Representative images of
a myelinating culture after 28 days in vitro (DIV) and stained for SMI-31 (red, neurons) and proteolipid protein (PLP, green,
myelin), plated onto either glass coverslips (A), low molecular weight PCL (B), high molecular weight PCL (C), poly-
carbonate (D), poly(methyl) methacrylate (PMMA) (E), polystyrene (PS; F), poly-L-lactide (PLLA) (G), or poly-
dimethylsiloxane (PDMS) (H). Scale bar: 100mm. Quantitative analysis of neurite density (I; SMI-31 immunoreactivity in a
given area) and myelination ( J; measured by the percentage of neurite density occupied by myelin ensheathed axons in a
given area) show little change in the percentage of neurite density on each of the polymers, but significant decrease in
myelination compared with the glass coverslips ( J; n= 3, t-test, Bonferroni corrected, *p< 0.05), with PCL supporting the
greatest level of myelination among the polymers. Color images available online at www.liebertpub.com/tea
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Myelination is decreased on PCL substrates
compared to control
To investigate if the topological discontinuities the micro-
pattern, the pores, and the combined micropattern and pores
in the PCL membrane21,31 would affect CNS cell survival
and myelination, we compared cell biological properties
between CNS cultures on the PLL-coated flat PCL membrane
(Fig. 3B), the porous PCL membrane (Fig. 3C), and the
porous PCL membrane possessing an aligned micropattern
as substrates (Fig. 3D). After 28 DIV, myelination was an
average of 5% on the control glass coverslips, whereas it was
reduced to 2% when the cells were plated on each of the PCL
substrates (Fig. 3E this was a significant reduction in mye-
lination n= 3, t-test, Bonferroni corrected, *p < 0.05) compared
to control glass coverslips. Neither the topography nor the
presence of pores reduced the neurite density (Fig. 3F), or
prevented the outgrowth of processes despite a reduction in
myelination at this time. To test if potential contaminants
leaching from the PCL into the culture environment affected
myelination, cultures on glass were incubated with PCL
beads throughout. After 28 DIV, neither the neurite density
(80.2% – 0.3% for the control compared to 79.8% – 0.4% in the
presence of PCL beads), nor myelination was affected
(4.0% – 0.5% for control, 3.7%– 0.3% in the presence of PCL
beads). This suggests that factors leached from PCL did not
affect myelination.
Surface treatment of the PCL substrate fails
to enhance myelination
In an attempt to investigate whether extracellular matrix
(ECM) coatings would enhance myelination PCL, substrates
were coated with collagen (Fig. 4B), fibronectin (Fig. 4C), and
laminin (Fig. 4D), subsequent to plasma activation, but be-
fore cell seeding with the myelinating cultures (and astro-
cytes monolayer). These ECM proteins have been shown to
enhance myelination when in direct contact with neurons
plated on glass coverslips.32,33 PLL-coated PCl substrates
were used for comparison (Fig. 4E). After 28 days, the cul-
tures were immunolabeled with antibodies to SMI-31 (red)
and PLP (green) and myelination quantified. Each of the
surface treatments were detrimental to the survival and
differentiation of the cultures, with the neurite density sig-
nificantly decreased in the myelinating cultures plated on
laminin- treated PCL (Fig. 4F; n = 3, t-test, Bonferroni cor-
rected, *p< 0.05), suggesting that neurons did not survive
well nor extend as many neurites as seen on the control
substrate. The levels of myelination on all ECM-treated
substrates were significantly reduced compared to both glass
coverslips treated with PLL and PCL treated with PLL (Fig.
4G; n = 3, t-test, *p< 0.05). This suggests ECM treatment of the
PCL induces a change in the astrocyte monolayer making it
less supportive of myelination. A similar reduction in mye-
lination has been reported when astrocytes were plated on
the ECM molecule tenascin C.30
Oligodendrocyte differentiation on PCL is altered
compared to glass
To investigate if the the PCL substrate affected oligoden-
drocyte differentiation stages, cultures were immunolabeled
at 7 and 14 DIV for three oligodendrocyte lineage-specific
markers. These include the OPC markers, NG2 (Fig. 5A–D),
and A2B5 (Fig. 5E–H), and the immature oligodendrocyte
FIG. 3. Myelination is less when myelinating cultures are plated on PCL compared to glass coverslips and stained after 28
DIV. Representative images of myelinating cultures on different substrates immunolabeled for SMI-31 (red) and PLP (green)
after 28 DIV. Nuclei were visualized with DAPI. Control cultures on glass coverslips (A) show extensive neurite coverage, which
were ensheathed with myelin, whereas cultures plated on the nonporous PCL (B), porous PCL (C), and porous, micropatterned
PCL (D) contained similar neurite density, but less myelination. Quantification of both myelination (E) and neurite density (F),
respectively, for each of the PCL substrates showed a significant decrease in myelination compared to the glass (F; n= 3, t-test,
Bonferroni corrected, *p< 0.05). Scale bar: 100mm. Color images available online at www.liebertpub.com/tea
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marker, O4 (Fig. 5I–L). The myelinating cultures plated onto
PCL had a higher percentage of immature A2B5-positive (+ ),
and NG2-positive (+ ) oligodendrocyte lineage cells at both 7
DIV and 14 DIV compared to cells plated on glass coverslips.
However, the NG2 + cells had a less branched morphology,
indicative of a more immature phenotype, than those plated
on coverslips, which was especially apparent by 14 DIV. The
density of O4 immunoreactivity also covered a greater area
on the PCL compared to cultures plated onto glass cover-
slips, suggesting either a greater number of O4 + cells, or
more extensive arborisation. As the cell density was so high,
it was difficult to accurately count individual cells; so, values
for O4 immunoreactivity was divided by DAPI-positive
nuclei. At day 21, expression of the mature myelin marker,
PLP, demonstrated that oligodendrocytes in the myelinating
cultures on the glass coverslips had already begun to mye-
linate, with detectable sheaths forming (Fig. 5M), while on
the PCL, the oligodendrocyte morphology was consistent
with a premyelinating phenotype, morphologically similar to
the O4 + cells observed at earlier time points on glass. Taken
together, this data suggests that there is a delay in the
maturation of oligodendrocytes in the myelinating cultures
plated onto PCL, with a larger proportion of immature and
premyelinating oligodendrocytes present (Fig. 5N bar
charts).
Myelination on PCL substrate is delayed compared
to cultures plated on glass coverslips
To assess if the greater number of immature oligoden-
drocytes in the cultures plated on PCL (Fig. 5) after 28 DIV
and the delay in myelination was a timing issue, we ex-
tended the culture period to 46 DIV. (Fig. 6). With the ex-
ception of the nonporous PCL (Fig. 6B), myelination on the
PCL substrates after 46 days was comparable (t-test, n= 3,
Bonferroni corrected, *p < 0.05) to cultures on glass cover-
slips (Fig. 6A), suggesting that oligodendrocyte differenti-
ation is delayed, and not inhibited on PCL. The neurite
density for each of the conditions was comparable with no
obvious signs of culture deterioration on any substrate.
With the micropatterned porous PCL being the final design
for the rolled 3D scaffold, this was the substrate used for
further investigation.
The astrocyte substrate can influence myelination
Our previous data suggested that the reactive status/
phenotype of astrocytes and the subsequent changes in fac-
tors secreted by these can affect myelination.24,30 To examine
if the substrate influence on myelination was mediated via
astrocyte secreted factors, we included a monolayer of as-
trocytes plated either onto glass coverslips (cond. CS, Fig.
7D) or onto PCL substrates (cond. PCL, Fig. 7B) in the Petri
dish containing myelinating cultures plated PCL substrates
or glass coverslips, respectively. After 28 DIV, the myeli-
nating cultures plated on glass coverslips, conditioned by
coculture with astrocytes plated on PCL (Fig. 7B; labeled
with the SMI-31 antibody (red) and anti-PLP (green)) had
significantly less myelination compared to control cultures
plated on glass (Fig. 7A). This indicates that astrocytes plated
on PCL produce, and release (a) secreted factor(s) that con-
tribute to a delay in myelination independent of direct cell
contact. Interestingly, the myelinating cultures plated on
astrocytes on PCL cocultured with a monolayer of astrocytes
plated on glass coverslips (Fig. 7D) had levels of myelination
comparable to cultures plated on glass coverslips (Fig. 7A; t-
test, n = 3, Bonferroni corrected, *p< 0.05) suggesting the de-
lay in myelination on the PCL substrate can be overcome by
promyelinating factors secreted by astrocytes, which were
cultured on glass.
FIG. 4. Surface treatments fail to enhance myelination on PCL. Representative images of myelinating cultures plated onto
either glass coverslips (A) or PCL coated with collagen (B); fibronectin (C) and laminin (D), or poly-l-lysine (PLL) alone (E).
Quantification of neurite density for the cultures on each substrate shows that, with the exception of the cultures plated on
laminin, neurite density was comparable to the glass coverslips (F). Quantification of the percentage of myelination (G)
showed a significant decrease compared to both the glass coverslip and PCL treated with PLL only (n = 3, t-test, Bonferroni
corrected, *p< 0.05). Scale bar: 100mm. Color images available online at www.liebertpub.com/tea
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Discussion
The ability of CNS cells to survive and differentiate ap-
propriately on an implantable scaffold that both aligns and
supports the viability of cell grafts is a prerequisite for an
effective scaffold design to be used as part of a strategy for
the treatment of SCI. Cell viability within scaffolds after
implantation can be an issue as seen with poly-D lactide
matrices plated with immature astrocytes.34 We have used a
PCL embossed, aligned micropattern scaffold containing
pores and microgrooves plated with mixed dissociated spi-
nal cord cells mimicking the CNS that will contact the scaf-
fold after implantation, to investigate the effect of several
polymers on these cells ability to survive and differentiate.
We found that PLL-coated PCL was the optimal substrate to
support myelination and inclusion of surface topography
necessary for generating a future 3D design did not affect
these properties. However, we also found that myelination in
these cultures plated onto PCL is delayed compared to
controls, due to differences in oligodendrocyte maturation.
This suggests a substrate-specific effect of the PCL upon CNS
cells within the culture. From astrocyte conditioning exper-
iments (Fig. 7), the reduction in myelination is unlikely to
be a direct, contact-mediated effect of PCL; it seems more
likely that the PCL substrate alters the secretory profile of
astrocytes.
Although myelinating cultures focus on in vitro interac-
tion, they enable examination of many aspects of cell inter-
actions that occur in the intact CNS, including cross talk
between astrocytes, neurons, and multiple glia.35 Im-
portantly, these cultures allow the study of myelin sheath
formation, rather than relying entirely on the expression of
late myelin markers. Myelin ensheathment observed in these
cultures is similar to myelination and sheath formation
in vivo.23–26 One important feature of the myelinating culture
is ensuring that the neurite density is comparable between
FIG. 5. Oligodendrocyte differentiation on PCL membranes is altered compared to glass coverslips. Representative images
of myelinating cultures plated onto coverslips (A, C, E, G, I, K, M) or PCL (B, D, F, H, J, L, N) immunolabeled for NG2 (A–
D), A2B5 (E–H), or O4 (I–L), markers of increasing oligodendroglial maturity at both 7 DIV and 14 DIV, with the percentage
of A2B5 + cells and NG2 + cells calculated from a total cell number as indicated by DAPI (blue) staining. The total coverage of
O4 + processes was also calculated and divided by the total DAPI count to give a ratio of O4 + coverage to total cell number.
At 7 DIV, a significantly higher percentage of NG2 + cells (n= 3, t-test, *p < 0.05), were observed on the PCL compared with
the coverslips, with this trend detectable at both 7 DIV and 14 DIV with regard to the percentage of A2B5 + cells and O4 +
coverage (significant for 7 DIV, when myelinating cultures on PCL were compared with coverslips, n = 3, t-test, *p< 0.05),
suggesting a greater number of oligodendrocytes on the PCL. At 21 DIV (M), the morphology of the oligodendrocytes
detectable with PLP immunolabeling, indicated the presence of what were likely to be myelin sheaths (yellow arrows) in the
cultures on the coverslips, whereas those on the PCL still possessed an immature morphology. Scale bar: 100mm. Color
images available online at www.liebertpub.com/tea
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FIG. 6. Myelination on PCL membranes reaches control levels over extended culture time. Representative images of
myelinating cultures on glass coverslips (A), nonporous PCL (B), porous PCL (C), and porous, micropatterned PCL (D),
immunolabeled for SMI-31 (red), and PLP (green). Quantification of neurite density (E) showed levels were similar on all
membranes tested. Quantification of myelination (F) demonstrates that myelination on the PCL membranes is comparable to
that found on glass coverslip control (n= 3, t-test, Bonferroni corrected, *p< 0.05). Scale bar: 200 mm. Color images available
online at www.liebertpub.com/tea
FIG. 7. Astrocytes plated on PCL delay myelination. Representative images of myelinating cultures plated on: glass
coverslips (A, B) and PCL (C, D), with the cultures undergoing conditioning by either astrocytes plated onto PCL (B), or
astrocytes plated onto coverslips (D). Cultures were immunolabeled for SMI-31 (red) and PLP (green). Scale bar: 100 mm.
Quantification of neurite density (E) showed that there were no significant differences for each substrate; however, quan-
tification of myelination (F) demonstrated that cultures plated on PCL conditioned with astrocytes plated on glass coverslips
(D) had levels of myelination comparable to cultures plated on glass coverslips. Conversely, myelinating cultures plated on
glass coverslips and conditioned with astrocytes plated on PCL (B) displayed significantly lower levels of myelination
compared to control cultures plated on glass coverslips (All n = 3, t-test, Bonferroni corrected, *p< 0.05). Color images
available online at www.liebertpub.com/tea
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control and experimental cultures. A low neurite density
suggests that viability may be compromised and the
number of neurites available for myelination is decreased
affecting the level of myelination calculated (less total
neurites/myelin sheath would give a higher percentage of
myelinated fibers). Despite comparable neurite densities
between each of the polymers tested, a significantly reduced
level of myelination was observed in the cultures at 28 DIV
compared to control cultures plated on glass coverslips,
suggesting that all the substrates affected myelination. With
PLLA, PGLA, and polycarbonate, all of which have been
considered as suitable potential candidates for transplan-
tation into CNS injury,36–40 this difference in supporting
myelination highlights the importance of examining inter-
actions of candidate substrates with CNS cells beyond just
neurite outgrowth. PDMS, on the other hand, is not a bio-
degradable material, even though it is extensively used in
biomedical engineering, incorporated into microscale de-
vices and permanent implants.40,41
The molecular weight of the macromer units can have a
significant effect on the final polymer interactions with
CNS cells, with a lower molecular weight PCL being more
supportive of myelination compared to the other polymers,
including a higher molecular weight PCL. The influence of
macromer weights on cells has been recognized in hydro-
gels,41 although the lower molecular weight PCL was un-
suitable for fabrication, as the PCL membrane degraded
during the embossing procedure. Thus, high molecular
weight PCL, which appeared to be the next best substrate,
was selected as the candidate material for further develop-
ment. Our results show that PCL appears to be a useful
support for CNS cells as it not only allows their adhesion,
survival, but also differentiation. Its potential use as a scaf-
fold for cell transplantation has added support by its long
degradation time.23,42 The degradation of radioactive-tagged
PCL transplanted subcutaneously into rats and followed
over 3 years was very slow. Over the first 2 years it broke
down into small molecular weight material by random,
spontaneous hydrolysis, eventually the degraded material
would be metabolized, although its overall shape still was
recognizable (Sun et al. 2006). Thermoplastic forming similar
to the manipulations needed to shape the scaffold presented
here do not affect the degradation time as shown by Lam
et al. (2008). As repair in the CNS is predicted to take a
relatively long time, it is thought that a PCL scaffold would
allow enough time for nerves and endogenous cells to re-
grow across the scaffold and become myelinated, and secrete
the appropriate ECM to bridge the lesion, before the scaffold
degrades.
Previous work using myelinating cultures has demon-
strated that between 24–28 DIV was sufficient to assess
myelination levels and was used in initial studies of the PCL
scaffolds with topographical features important for the final
design of a 3D scaffold for implantation in vivo.21,31 How-
ever, the significantly lower level of myelination at 28 DIV
across the PCL substrates irrespective of topographical fea-
tures, compared with control cultures suggested a dominant,
substrate-specific effect. This effect of PCL on myelination
was not due to cytotoxicity due to impurities in the PCL or
degradation products43 or the higher hydrophobicity of PCL
when compared to glass coverslips. ECM molecules (colla-
gen, fibronectin, and laminin), traditionally used in neuronal
cultures to promote survival and neurite outgrowth,44–47 did
not enhance myelination. The myelinating cultures plated
onto PCL coated with laminin displayed significantly lower
neurite outgrowth than the other conditions, even though the
astrocyte monolayer, critical for neurite survival in this sys-
tem, was intact. The possibility exists that a more specific
treatment regime is required for the ECM molecules to pro-
mote myelination. However, a similar reduction in myeli-
nation was observed when astrocytes were plated on glass
coverslips coated with the ECM molecule tenascin C.30 A
subsequent microarray study of astrocytes plated either on
tenascin C or PLL identified the chemokine CXCL10 as a
factor secreted by astrocytes, which inhibited myelination.
Thus, this data further supports the concept that modifica-
tion of the astrocyte phenotype by ECM molecules influences
glial/axonal interactions.30,48
To dissect how myelination was perturbed on PCL, we
observed oligodendrocyte differentiation from progenitor
cell to maturity using a panel of markers. There were a
greater number of early OPCs, immature oligodendrocytes,
and premyelinating oligodendrocytes, but less mature oli-
godendrocytes. These data coupled with decreased myeli-
nation and apparent ensheathment with anti-PLP and the
recovery of myelination to control levels at 46 DIV suggested
that although PCL delayed oligodendrocyte differentiation,
this was not detrimental to myelination.
Previously, we and others have shown the astrocyte re-
active status or phenotype can influence myelination30,48–51
within myelinating cultures. Astrocytes made quiescent by
plating on tenascin C52 reduced the percentage of myelina-
tion in cultures plated onto them. Since quiescent astrocytes
(plated on tenascin C) were shown to secrete an inhibitory
factor for myelination, CXCL10, astrocytes on PCL could
conceivably secrete factors that have a similar effect.30
However, the effect is also reversible as seen by the
enhancement of myelination following exposure to astrocyte-
conditioned media from astrocytes grown on glass cover-
slips. Thus, we suggest that astrocytes plated on PCL initially
have a phenotype less supportive for myelination; however,
they adopt a phenotype conducive of myelination over time.
This delay of myelination mediated by the influence of PCL
on the astrocytes can be overcome by factors secreted by
astrocytes plated on coverslips. These astrocytes appear to
secrete factors that either directly promote myelination or
counteract the delaying effect of PCL on myelination. These
findings suggest that the effects of PCL on myelination are, at
least, in part, an indirect one, by proxy of the astrocyte
monolayer, altering their secretory profile.
Conclusion
In this study, we have confirmed that a PCL scaffold with
topography is a suitable substrate for the design of a 3D
scaffold for inplantation into animal models of SCI. Fur-
thermore, myelination was delayed on the PCL substrate by
factors secreted by astrocytes. However, this short delay was
not a caveat for the use of PCL in the design of a 3D scaffold
for transplantation into the injured CNS.
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